Home > Insider Trading > Filing (0001104659-18-042317)

Filing Details

Accession Number:: 0001104659-18-042317
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-26 16:57:11
Reporting Period:: 2018-06-25

Accepted Time:: 2018-06-26 16:57:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674365	Aptinyx Inc.	APTX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1625653	New Leaf Ventures Iii, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625656	New Leaf Venture Associates Iii, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625657	New Leaf Venture Management Iii, L.l.c.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625693	New Leaf Bpo Associates I, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625696	New Leaf Biopharma Opportunities I, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-25	1,047,450	$0.00	1,047,450	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-06-25	1,197,076	$0.00	2,244,526	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-06-25	552,208	$0.00	2,796,734	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-06-25	243,345	$0.00	243,345	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-06-25	125,000	$16.00	2,921,734	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2018-06-25	125,000	$16.00	368,345	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2018-06-25	28,895,188	$0.00	1,047,450	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2018-06-25	33,022,786	$0.00	1,197,076	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-06-25	15,233,315	$0.00	552,208	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-06-25	6,712,986	$0.00	243,345	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.
These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities.
Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. ("NLV Biopharma"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. ("NLBA-I"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering.